<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="953">
  <stage>Registered</stage>
  <submitdate>28/10/2005</submitdate>
  <approvaldate>28/10/2005</approvaldate>
  <nctid>NCT00247390</nctid>
  <trial_identification>
    <studytitle>Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.</studytitle>
    <scientifictitle>A Randomised, Double-blind, Placebo-controlled Study to Determine the Long-term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004-004351-20</secondaryid>
    <secondaryid>TAK-375-EC302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Insomnia</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ramelteon
Treatment: drugs - Placebo

Experimental: Ramelteon 8 mg QD - 

Placebo Comparator: Placebo QD - 


Treatment: drugs: Ramelteon
Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.

Treatment: drugs: Placebo
Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean change in Latency to Persistent Sleep of 2-night polysomnogram.</outcome>
      <timepoint>Months 3 and 6 or Final Visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Total Sleep Time from polysomnogram, on 2 nights over 6 months.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Subjective Sleep Latency by postsleep questionnaire on 2 nights over 6 months.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Subjective Total Sleep Time by postsleep questionnaire on 2 nights over 6 months.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Subjective Number of Awakenings by postsleep questionnaire.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in Subjective Sleep Quality by postsleep questionnaire.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Sleep Time in rapid eye movement (REM) sleep as determined by polysomnogram.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Sleep Time in stage 1 non-rapid eye movement (NREM) sleep as determined by polysomnogram.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Sleep Time in stage 2 non-rapid eye movement (NREM) sleep as determined by polysomnogram.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Sleep Time in stage 3/4 non-rapid eye movement (NREM) sleep as determined by polysomnogram.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Sleep Time in stage 1 sleep as determined by polysomnogram.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Latency to Rapid Eye Movement as determined by polysomnogram.</outcome>
      <timepoint>Week 1 and Months 1, 3, 5 and 6 or Final Visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Body mass index between 18 and 34, inclusive.

          -  Based on sleep history, has had chronic insomnia for at least 3 months.

          -  Based on sleep history, reports a subjective sleep latency greater than or equal to 45
             min and a subjective total sleep time less than or equal to 6.5 hours.

          -  Based on sleep history, habitual bedtime is between 10:00 PM and 1:00 AM.

          -  Mean latency to persistent sleep of greater than 20 minutes on two consecutive
             screening nights with neither night less than 15 minutes. Also, a mean of 60 minutes
             of wake time during the 480 minutes in bed across two nights with no night less than
             45 minutes.

          -  Based on sleep history, normally uses pharmacological assistance to sleep 0 to 4 times
             per week in the last 3 months.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria

          -  Known hypersensitivity to ramelteon or related compounds, including melatonin, and
             melatonin related compounds.

          -  Participated in any other investigational study and/or taken any investigational drug
             within 30 days or five half-lives prior to the first dose of single-blind study
             medication, whichever is longer.

          -  Sleep schedule changes required by employment (eg, shift worker) within three months
             prior to the administration of single-blind study medication.

          -  Flown across greater than three time zones within 7 days prior to or during screening.

          -  Participated in a weight loss program or has substantially altered their exercise
             routine within 30 days prior to the administration of single-blind study medication.

          -  Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg
             movement syndrome, chronic obstructive pulmonary disease or fibromyalgia.

          -  History of psychiatric disorder within the past 6 months.

          -  History of alcohol abuse within the past 12 months, as defined in Diagnostic &amp;
             Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes
             more than 14 alcoholic drinks per week, or consumed any alcoholic drinks within 24
             hours of any polysomnogram visits.

          -  History of drug abuse within the past 12 months, as defined in Diagnostic &amp;
             Statistical Manual of Mental Disorders, 4th Edition Revised.

          -  Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal,
             pulmonary, hematologic, neurological, or metabolic disease, unless currently
             controlled and stable with protocol-allowed medication, within 30 days prior to the
             first night of single-blind study medication.

          -  Apnea hypopnea index (per hour of sleep) greater than 10 as seen on the first
             polysomnogram screening night.

          -  Periodic Leg Movement Syndrome with arousal index (per hour of sleep) greater than 10
             as seen on the first polysomnogram screening night.

          -  Positive urine drug screen at Screening Visit 1 or any of the polysomnogram assessment
             visits.

          -  Positive breathalyzer test on any of the polysomnogram assessment visits.

          -  Uses tobacco products (including nicotine gum and patch) or any other products that
             may interfere with the sleep wake cycle during nightly awakenings.

          -  Used any central nervous system medication or other drugs or supplements known to
             affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is
             longer) prior to the administration of single-blind study medication. These
             medications must not have been used to treat psychiatric disorders.

          -  Intends to continue taking any disallowed medication or any prescription medication or
             over the counter medication that is known to affect the sleep/wake function or
             otherwise interfere with evaluation of the study medication. The subject must report
             all prescription and over the counter medications taken in the three weeks prior to
             screening.

          -  Is required to take or continues taking any disallowed medication, prescription
             medication, herbal treatment or over-the counter medication that may interfere with
             evaluation of the study medication, including:

               -  Anxiolytics

               -  Sedatives

               -  Hypnotics

               -  CNS active drugs (including herbal)

               -  Antidepressants

               -  Narcotic analgesics

               -  Anticonvulsants

               -  Beta blockers

               -  Sedating H1 antihistamines

               -  St. John's Wort

               -  Systemic steroids

               -  Kava-kava

               -  Respiratory stimulants

               -  Ginkgo-biloba

               -  Decongestants

               -  Over-the-counter and prescription stimulants

               -  Antipsychotics

               -  Over-the-counter and prescription diet aids

               -  Muscle Relaxants

               -  Melatonin and all other drugs or supplements known to affect sleep/wake function

          -  Any additional condition(s) that in the Investigator's opinion would

               -  affect sleep/wake function

               -  prohibit the subject from completing the study

               -  indicate that continuation in the study would not be in the best interests of the
                  subject.

          -  History of hepatitis B or hepatitis C.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>451</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Adelaide</hospital>
    <hospital> - Camperdown</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Victoria</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Victoria</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ceske Budejovice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava-Poruba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Espoo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clamart Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Garches</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rouffach</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Goettingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwalmstadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwerin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Irkutsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Samara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Yekateringburg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Takeda</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study to determine the long-term efficacy and safety of ramelteon, once
      daily (QD).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00247390</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director Clinical Science</name>
      <address>Takeda</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>